2023-07-31 08:46:52 ET
- Checkpoint Therapeutics ( NASDAQ: CKPT ) has entered into a definitive agreement for the issuance and sale of an aggregate of ~3.24M shares of its common stock, ~3.24M of Series A and B warrants to purchase up to 3.2M shares, at a purchase price of $3.09 /share of common stock and associated warrants, in a registered direct offering priced ATM.
- The gross proceeds from the offering are expected to be approximately $10M.
- The net proceeds of this offering for working capital and general corporate purposes, including the manufacturing of cosibelimab and certain pre-commercial activities in anticipation of potential approval and commercial launch.
- The closing of the offering is expected to occur on or about July 31, 2023.
For further details see:
Checkpoint to sell 3.2M shares at $3.09 in registered direct offering